News

European Commission (EC) has published a new version of the Questions & Answers document on “Safety Features for Medicinal Products for Human Use (V.19)”.

The European Commission has taken decision to extend the transitional period for a period of three years, which was determined in the context of the action of the medicine verification system regarding the medicine products exported to the United Kingdom* (UK) following its’ withdrew from the European Union.

Welcome to the “EMVS Community Holiday Bulletin 2021”, a collaboration between the European Medicines Verification Organisation (EMVO) and the National Medicines Verification Organisations (NMVOs).

EMVO informs, that prototype and first phase of development for AMS HUB has been completed. AMS HUB solution is currently under system test by provider (started at September 17). Next milestone would be production pilot phase – October 4.

The Latvian Medicines Verification System (LZVS) has successfully passed all compatibility tests so that the Latvian national system is prepared for European Medicines Verification System (EU Hub) updates / system release 1.9. LZVS is ready to work without interruption and restriction

On 13 January 2021, the European Commission adopted a new Delegated Regulation, amending Delegated Regulation (EU) 2016/161 as regards a derogation from the obligation of wholesalers to decommission the unique identifier of products exported to the United Kingdom.